Exact Sciences Corporation (NASDAQ:EXAS) was downgraded by Vetr from a “buy” rating to a “hold” rating in a report issued on Thursday. They currently have a $36.37 price target on the medical research company’s stock. Vetr‘s target price would suggest a potential upside of 0.97% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Roth Capital restated a “buy” rating and set a $40.00 price objective (up previously from $33.00) on shares of Exact Sciences Corporation in a research note on Thursday, June 1st. ValuEngine upgraded Exact Sciences Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Stephens set a $28.00 price target on Exact Sciences Corporation and gave the stock a “hold” rating in a research report on Wednesday, June 7th. Robert W. Baird reiterated an “outperform” rating and set a $40.00 price target on shares of Exact Sciences Corporation in a research report on Thursday, June 1st. Finally, Jefferies Group LLC set a $35.00 price target on Exact Sciences Corporation and gave the stock a “buy” rating in a research report on Thursday, June 1st. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $33.08.

Exact Sciences Corporation (EXAS) traded down 0.14% during midday trading on Thursday, hitting $36.02. 1,516,012 shares of the stock traded hands. The firm’s market cap is $4.01 billion. Exact Sciences Corporation has a 12 month low of $11.48 and a 12 month high of $38.92. The company’s 50 day moving average price is $33.86 and its 200 day moving average price is $24.14.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its earnings results on Thursday, April 27th. The medical research company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.09. Exact Sciences Corporation had a negative return on equity of 49.24% and a negative net margin of 116.39%. The company had revenue of $48.36 million during the quarter, compared to the consensus estimate of $37.38 million. During the same quarter in the prior year, the business earned ($0.49) earnings per share. The company’s revenue was up 225.9% compared to the same quarter last year. Equities research analysts predict that Exact Sciences Corporation will post ($1.34) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/07/06/vetr-inc-downgrades-exact-sciences-corporation-nasdaqexas-to-hold.html.

In related news, SVP D Scott Coward sold 1,987 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $35.21, for a total transaction of $69,962.27. Following the completion of the sale, the senior vice president now directly owns 57,603 shares in the company, valued at $2,028,201.63. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.00% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in EXAS. Suntrust Banks Inc. raised its stake in shares of Exact Sciences Corporation by 1.5% in the first quarter. Suntrust Banks Inc. now owns 18,478 shares of the medical research company’s stock valued at $436,000 after buying an additional 277 shares in the last quarter. Stifel Financial Corp raised its stake in shares of Exact Sciences Corporation by 1.5% in the first quarter. Stifel Financial Corp now owns 21,475 shares of the medical research company’s stock valued at $506,000 after buying an additional 310 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of Exact Sciences Corporation by 3.0% in the first quarter. Prudential Financial Inc. now owns 11,141 shares of the medical research company’s stock valued at $263,000 after buying an additional 320 shares in the last quarter. Baker Avenue Asset Management LP raised its stake in shares of Exact Sciences Corporation by 2.3% in the first quarter. Baker Avenue Asset Management LP now owns 35,251 shares of the medical research company’s stock valued at $833,000 after buying an additional 795 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of Exact Sciences Corporation by 1.0% in the first quarter. Swiss National Bank now owns 179,319 shares of the medical research company’s stock valued at $4,236,000 after buying an additional 1,700 shares in the last quarter. Institutional investors and hedge funds own 84.96% of the company’s stock.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.